Navigation Links
Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded

WITTEN, Germany, October 29 /PRNewswire-FirstCall/ -- The comparative study of chronic wound treatment at the Hospital Civil of Cd. Victoria, Tamaulipas, Mexico, was concluded successfully. Due to the significantly superior therapeutic success the Ministry of Health ordered the control to be abandoned and moved to Hemospray treatment for ethical reasons. 22 of the 24 patients within the Hemospray group were healed completely, while 22 of the 24 patients of the control group showed no comparable progress. Moreover, additional patients suffering from diabetic foot disease were successfully treated with Hemospray. The total healing ratio is significantly higher than 75%.

These results were presented to health system representatives of several Latin American countries in Mexico City by the Chief Investigator of the study.

The results are currently being evaluated by the State Health Authorities of Tamaulipas who sponsored the study.

Apart from this, a considerable share of the patient data were crosschecked and evaluated by Sangui in Witten. It turned out that these data confirm the results as previously indicated. Sangui regards this outcome as a confirmation of the outstanding efforts made by the teams on location and as a great success of its systematic competence in wound healing.

SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc. ( SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information please contact:

    Joachim Fleing
    Phone: +49(160)741-27-17
    Fax: +49(2302)915-191

SOURCE Sangui Bio Tech International Inc.

SOURCE Sangui Bio Tech International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
2. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
3. Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmers Trabecular Metal(TM) Technology
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. Wound Management Technologies (OTCBB- WNDM) Signs Biotech Agreement With Biocure S.r.l. of Milan, Italy
6. Derma Sciences Announces Multiple Clinical Presentations of MEDIHONEY(R) at Upcoming Major Wound Care Conference
7. Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference
8. Wound Management Technologies Acquires Resorbable Orthopedics
9. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
10. New Data Supports ConvaTec Negative Pressure Wound Therapy
11. New Powder Speeds Healing of Difficult Foot Wounds
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology:
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction ... , “We wake up every day excited to rebuild lives and it’s an honor ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/26/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact ... and reliability. , The new Q-Suite 6 platform is based on the latest Java ... into a specific piece of software for many key components of the suite. Much ...
Breaking Medicine News(10 mins):